According to visionary Sebastian Brunemeier, only recently have we been able to understand the “fundamental molecular and cellular biology of the aging process.” Newfound technologies have allowed scientists to extend the healthy lifespan of mice by up to 30%, and he believes this research can, and will, eventually be applied to slow the aging process for humans as well. But how big is the market around longevity biotech? Since welcoming early investors like Peter Thiel and Bob Nelson, Brunemeier says there’s “a huge industry building around longevity biotech” and reveals the potential for economic change. Recorded on February 18, 2022.